Table 5.

Response rates and duration of responses for systemic treatments for MF/SS.

Treatment	Staging	Overall response (%)	Complete response (%)	Response Duration	References
Isotretinoin	MF/ SS	43–80	8–33	RD: 3-15 months	22, 23
Acitretin	Ia–IV	59–64	4–34.6	RD: 28 months	22, 23, 24
Bexarotene	I–IIa	54–67	7–27	RD: 9.9-17.2 months	23, 25
	≥IIb	45–54	2–13		23, 25
Alpha interferon	Ia–IVa	29–80	4–67	RD: 5-8 months	26, 29
Pegylated alpha-interferon	Ib–III	50–83	33–67	–	28
Pegylated liposomal doxorubicin	Ib–IV	41–88	6	RD: 6-13.3 months	32, 33
Gemcitabine	T3–T4	47–70	11.5–22	RD: 10-15 months	34, 38
Chlorambucil	SS	85	35	RD: 16.5 months	36
	III–IVb	100	53.8		35
Methotrexate, low dose	T2	33	33	RD: 15 months	39
	III	56	41	RD: 31 months	39
Pralatrexate	IIa–IV	40.8	6.1	RD: 6 months	40
Romidepsin	IIb	34–38	6–7	RD: 15 months	41
Vorinostat	Ib–IVa	30	–	RD: 5 months	42
Alemtuzumab	adv. MF–SS	38–84	0–47	RD: 4 months	44, 45
Brentuximab vedotin	Ia–IVb	50	10	TNT: 13.4 months	46
Mogamulizumab	Ia–IVb/SS	28 (MF: 21; SS: 37)	-	PFS: 7.7 months	47
CHOP	IIb	66	–	TNT: 5.7 months	38
EPOCH	IIb–IV	80	–	PFS: 8 months	38
Fludarabine + CFM	IIb–III	55	–	RD: 10 months	38
Fludarabine + IFN	IIa–IVb	40–58	–	PFS: 5.9 months	38
IFN + PUVA	Ia–IVa	80.6	75	RD: 32 months	30
		–	–	PFS, 5 years: 75%	30
	Ia–IIa	98	84	PFS, 5 years: 27%	31
IFN peg + PUVA	Ia–IV	88	44	PFS: 30.9 months	27
IFN + retinoid	Ia–IIb	38	6	–	29
Bexaroteno + PUVA	Ib–IIa	77	31	RD: 5.8 months	52
Isolated ECP	III–IVa1	24	9	TNT: 14 months	49, 50, 51
ECP + IFN	III–IVa1	45.4	18.2	–	49, 50
ECP + IFN + Bexarotene	III–IVa1	88.2	32.4	RD: 4 months	49, 50

PFS, Progression-Free Survival; RD, Response Duration; TNT, Time to Next Treatment; adv. MF, Advanced Mycosis Fungoides; SS, Sézary syndrome;; CHOP, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone; EPOCH, Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisolone; ECP, Extracorporeal Photopheresis; CFM, Cyclophosphamide; IFN, Interferon; peg. IFN, pegylated Interferon.